In the BioHarmony Drug Report Database

"Preview" Icon

Teprotumumab

Tepezza (teprotumumab) is an antibody pharmaceutical. Teprotumumab was first approved as Tepezza on 2020-01-21. It is used to treat graves ophthalmopathy in the USA. The pharmaceutical is active against insulin-like growth factor 1 receptor.

 

Trade Name

 

Tepezza
 

Common Name

 

teprotumumab
 

ChEMBL ID

 

CHEMBL1743079
 

Indication

 

graves ophthalmopathy
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Teprotumumab structure rendering